The PBD Biotech international management team brings together expertise in diagnostics, clinical and veterinary science, disease management and policy.
About PBD Biotech
PBD Biotech has developed a phage-based diagnostic for tuberculosis - a powerful tool in the fight to eradicate this devastating disease.
PBD Biotech and its diagnostic Actiphage have been recognised by the veterinary, dairy and farming industries with awards for innovation.
PBD Biotech Limited specialises in the use of novel phage-based technology for the detection of tuberculosis and related mycobacterial diseases in the fields of human and veterinary diagnostics.
The company has developed proprietary technology that can be used to detect the presence of mycobacteria such as: Mycobacterium tuberculosis (Human TB), second only to Covid as a fatal infectious disease; Mycobacterium (bovine TB) and Mycobacterium avium subsp. paratuberculosis (MAP; Johne’s disease), which are both significant causes of loss of profitability in the agricultural industry.
The company was co-founded in 2018, by: Prof. Cath Rees, Professor in Microbiology at the University of Nottingham and Chief Scientific Officer at PBD Biotech; Dr Ben Swift, Research Fellow in Antimicrobial Resistance, Royal Veterinary College and Director of Research and Development at PBD Biotech; together with serial entrepreneur Dr Berwyn Clarke.
The registered office is at Grosvenor House, Birmingham, UK.
Actiphage is industry recognised:
- 2019 Royal Dairy Innovation Award, awarded by the Royal Association of British Dairy Farmers (RABDF)
- Cream Award for Innovation 2020, organised by British Dairying to promote best practice and recognise some of the brightest and best businesses and people across the industry
- Vet Record Innovation Award 2021, where Actiphage was described by head judge, Professor the Lord Trees, as “having the potential to be a game-changer in tackling bTB”
Related content
Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic with potential to revolutionise management of TB.
Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic...
PBD Biotech is expanding its North American team. Tuberculosis (TB) and Johne’s Disease expert Tom Kellner has been appointed as Director of Operations in North America, to advise on regulatory affairs and provide technical and customer support.
PBD Biotech is expanding its North American team. Tuberculosis (TB) and Johne’s Disease expert Tom Kellner has been appointed as...
Innovation directed at an unmet market need can stimulate economic development if the value creation is kept within the local economy. The recent pandemic has shown the huge value of diagnostics and tuberculosis (TB), for which there are currently few...
Innovation directed at an unmet market need can stimulate economic development if the value creation is kept within the local...
PBD Biotech, developers of a phage-based diagnostic for tuberculosis, is moving to the next stage of its development. It is appointing Jane Theaker, of precision medicine company Kinomica, as the new CEO and bringing Commercial Director, Jonnie Yewdall, into a...
PBD Biotech, developers of a phage-based diagnostic for tuberculosis, is moving to the next stage of its development. It is...
